108 related articles for article (PubMed ID: 9750501)
1. [Prostate specific antigen doubling time in prostate cancer before treatment and in refractory status].
Nakata S; Takezawa Y; Kobayashi M; Kuribara H; Matumoto K; Kosaku N; Suzuki T; Yamanaka H
Nihon Rinsho; 1998 Aug; 56(8):2026-30. PubMed ID: 9750501
[TBL] [Abstract][Full Text] [Related]
2. [PSA-doubling time immediately before the diagnosis of prostate cancer].
Nakata S; Hasumi M; Suzuki T; Sato J; Imai K; Yamanaka H; Shimizu T
Hinyokika Kiyo; 1998 Feb; 44(2):81-4. PubMed ID: 9546125
[TBL] [Abstract][Full Text] [Related]
3. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
[TBL] [Abstract][Full Text] [Related]
4. Outcome of patients with hormone-refractory prostate cancer: prognostic significance of prostate-specific antigen-doubling time and nadir prostate-specific antigen.
Tomioka S; Shimbo M; Amiya Y; Nakatsu H; Murakami S; Shimazaki J
Jpn J Clin Oncol; 2008 Jan; 38(1):36-42. PubMed ID: 18258713
[TBL] [Abstract][Full Text] [Related]
5. Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy.
Soergel TM; Koch MO; Foster RS; Bihrle R; Wahle G; Gardner T; Jung SH
J Urol; 2001 Dec; 166(6):2198-201. PubMed ID: 11696735
[TBL] [Abstract][Full Text] [Related]
6. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml.
Shariat SF; Abdel-Aziz KF; Roehrborn CG; Lotan Y
Eur Urol; 2006 Feb; 49(2):293-302. PubMed ID: 16387412
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality.
Efstathiou JA; Chen MH; Catalona WJ; McLeod DG; Carroll PR; Moul JW; Roehl KA; D'Amico AV
Urology; 2006 Aug; 68(2):342-7. PubMed ID: 16904449
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
Lee AK; Levy LB; Cheung R; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
[TBL] [Abstract][Full Text] [Related]
9. Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure.
Ray ME; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Zelefsky MJ; Zietman AL; Kuban DA
Urology; 2006 Dec; 68(6):1257-62. PubMed ID: 17141830
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen doubling time among Japanese men in an annual health screening program.
Terai A; Matsui Y; Ichioka K; Ohara H; Terada N; Yoshimura K
Int J Urol; 2004 Oct; 11(10):856-61. PubMed ID: 15479290
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen doubling times in patients who have failed radical prostatectomy: correlation with histologic characteristics of the primary cancer.
Pruthi RS; Johnstone I; Tu IP; Stamey TA
Urology; 1997 May; 49(5):737-42. PubMed ID: 9145980
[TBL] [Abstract][Full Text] [Related]
12. Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancer.
Maffezzini M; Bossi A; Collette L
Eur Urol; 2007 Mar; 51(3):605-13; discussion 613. PubMed ID: 17113217
[TBL] [Abstract][Full Text] [Related]
13. Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy.
Simmons MN; Stephenson AJ; Klein EA
Eur Urol; 2007 May; 51(5):1175-84. PubMed ID: 17240528
[TBL] [Abstract][Full Text] [Related]
14. [Long-term follow-up of serum prostate-specific antigen after radiotherapy of prostatic carcinoma].
Schmid HP; Ferrari MK; Stamey TA
Helv Chir Acta; 1994 Dec; 60(6):1101-5. PubMed ID: 7533148
[TBL] [Abstract][Full Text] [Related]
15. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis.
Ray ME; Thames HD; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Shipley WU; Zelefsky MJ; Zietman AL; Kuban DA
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1140-50. PubMed ID: 16198506
[TBL] [Abstract][Full Text] [Related]
16. [Rising Prostate Specific Antigen following treatment with curative intention].
Jakobsen H; Pedersen KV
Ugeskr Laeger; 2007 May; 169(20):1907-9. PubMed ID: 17553369
[TBL] [Abstract][Full Text] [Related]
17. [PSA and follow-up after treatment of prostate cancer].
Benchikh El Fegoun A; Villers A; Moreau JL; Richaud P; Rebillard X; Beuzeboc P
Prog Urol; 2008 Mar; 18(3):137-44. PubMed ID: 18472065
[TBL] [Abstract][Full Text] [Related]
18. Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer.
Zelefsky MJ; Ben-Porat L; Scher HI; Chan HM; Fearn PA; Fuks ZY; Leibel SA; Venkatraman ES
J Clin Oncol; 2005 Feb; 23(4):826-31. PubMed ID: 15681527
[TBL] [Abstract][Full Text] [Related]
19. [Diagnostic methodology for the biochemical recurrence of prostate cancer after radical prostatectomy].
Serra AC; Narbón ES
Arch Esp Urol; 2006 Dec; 59(10):1041-52. PubMed ID: 17283717
[TBL] [Abstract][Full Text] [Related]
20. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy.
Ward JF; Blute ML; Slezak J; Bergstralh EJ; Zincke H
J Urol; 2003 Nov; 170(5):1872-6. PubMed ID: 14532796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
